Cervical spinal hemisection at C2 (SH) removes premotor drive to phrenic motoneurons located in segments C3-C5 in rats. Spontaneous recovery of ipsilateral diaphragm muscle activity is associated with increased phrenic motoneuron expression of glutamatergic N-methyl-Daspartate (NMDA) receptors and decreased expression of a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptors. Glutamatergic receptor expression is regulated by tropomyosin-related kinase receptor subtype B (TrkB) signaling in various neuronal systems, and increased TrkB receptor expression in phrenic motoneurons enhances recovery post-SH. Accordingly, we hypothesize that recovery of ipsilateral diaphragm muscle activity post-SH, whether spontaneous or enhanced by adenoassociated virus (AAV)-mediated upregulation of TrkB receptor expression, is associated with increased expression of glutamatergic NMDA receptors in phrenic motoneurons. Adult male Sprague-Dawley rats underwent diaphragm electromyography electrode implantation and SH surgery. Rats were injected intrapleurally with AAV expressing TrkB or GFP 3 weeks before SH. At 14 days post-SH, the proportion of animals displaying recovery of ipsilateral diaphragm activity increased in AAV-TrkBtreated (9/9) compared with untreated (3/5) or AAV-GFP-treated (4/10; P < 0.027) animals. Phrenic motoneuron NMDA NR1 subunit mRNA expression was approximately fourfold greater in AAV-TrkB-vs. AAV-GFPtreated SH animals (P < 0.004) and in animals displaying recovery vs. those not recovering (P < 0.005). Phrenic motoneuron AMPA glutamate receptor 2 (GluR2) subunit mRNA expression decreased after SH, and, albeit increased in animals displaying recovery vs. those not recovering, levels remained lower than control. We conclude that increased phrenic motoneuron expression of glutamatergic NMDA receptors is associated with spontaneous recovery after SH and enhanced recovery after AAV-TrkB treatment.
SH surgery. Rats were injected intrapleurally with AAV expressing TrkB or GFP 3 weeks before SH. At 14 days post-SH, the proportion of animals displaying recovery of ipsilateral diaphragm activity increased in AAV-TrkBtreated (9/9) compared with untreated (3/5) or AAV-GFP-treated (4/10; P < 0.027) animals. Phrenic motoneuron NMDA NR1 subunit mRNA expression was approximately fourfold greater in AAV-TrkB-vs. AAV-GFPtreated SH animals (P < 0.004) and in animals displaying recovery vs. those not recovering (P < 0.005). Phrenic motoneuron AMPA glutamate receptor 2 (GluR2) subunit mRNA expression decreased after SH, and, albeit increased in animals displaying recovery vs. those not recovering, levels remained lower than control. We conclude that increased phrenic motoneuron expression of glutamatergic NMDA receptors is associated with spontaneous recovery after SH and enhanced recovery after AAV-TrkB treatment. J. Comp. Neurol. 525:1192 -1205 , 2017 . INDEXING TERMS: neuroplasticity; neurotrophin; diaphragm muscle; phrenic motoneuron; spinal cord injury; RRID:RGD_5508397; RRID:SCR_010038; RRID:SCR_014325 Cervical segments of the spinal cord are most commonly involved in traumatic spinal cord injury (SCI), and, although injuries are frequently incomplete, cervical SCI results in significant respiratory impairment and the requirement for mechanical ventilation (National Spinal Cord Injury Statistical Center, 2015) . In a wellestablished model of incomplete cervical SCI, unilateral C2 spinal cord hemisection (SH), ipsilateral excitatory premotor drive to phrenic motoneurons is removed and the ipsilateral diaphragm muscle is inactivated. Over time after SH, there is a varying extent of spontaneous recovery of ipsilateral activity reflecting neuroplasticity and strengthening of spared excitatory drive to phrenic motoneurons (Boulenguez et al., 2007; Golder and Mitchell, 2005; Golder et al., 2003; Mantilla et al., 2013b; Miyata et al., 1995; Nantwi et al., 1999; Prakash et al., 1999; Sieck and Mantilla, 2009; Zhan et al., 1997) .
Excitatory bulbospinal (premotor) respiratory drive to phrenic motoneurons is primarily glutamatergic (Greer et al., 1992; McCrimmon et al., 1989; Saji and Miura, 1990) . Phrenic motoneurons express multiple excitatory glutamatergic receptor subtypes, including ionotropic Nmethyl-D-aspartate (NMDA) receptors and a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) receptors (Chitravanshi and Sapru, 1996; Robinson and Ellenberger, 1997) . Both NMDA and AMPA receptors located in the phrenic motor nucleus play an important role in neurotransmission of inspiratory drive, although the relative contribution remains controversial (Chitravanshi and Sapru, 1996; Pierrefiche et al., 1994; Robinson and Ellenberger, 1997) . Changes in glutamatergic receptor expression at motoneurons may contribute to neuroplasticity in conditions such as SCI. For instance, the time course of spontaneous recovery post-SH correlates with changes in phrenic motoneuron receptor expression of NMDA and AMPA receptors in which NMDA receptor expression increases and AMPA receptor expression decreases after SH (Alilain and Goshgarian, 2008; Mantilla et al., 2012) . Whether altered receptor expression reflects common mechanisms underlying recovery across models of spontaneous and enhanced recovery post-SH is presently unknown.
Glutamatergic receptor expression is regulated by tropomyosin-related kinase receptor subtype B (TrkB) signaling in various neuronal systems (Jovanovic et al., 2000; Kang and Schuman, 1995; Lin et al., 1998; Suen et al., 1997) . A recent series of studies from our laboratory showed that brain-derived neurotrophic factor (BDNF) signaling via TrkB kinase activity, specifically in phrenic motoneurons, is necessary and sufficient for recovery of ipsilateral rhythmic diaphragm muscle activity post-SH (Gransee et al., 2013 (Gransee et al., , 2015 Mantilla et al., 2013a,; Martinez-Galvez et al., 2016) . Accordingly, we hypothesize that recovery of ipsilateral rhythmic diaphragm muscle activity post-SH, whether spontaneous or enhanced by adenoassociated virus (AAV)-mediated upregulation of TrkB receptor expression in phrenic motoneurons, is associated with increased expression of glutamatergic NMDA receptors in phrenic motoneurons.
MATERIALS AND METHODS Animals and ethical approval
In total, 36 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) with an initial body weight of 220-300 g were assigned to two different surgery groups, control uninjured (n 5 12) and SH (n 5 24). Animal care, maintenance, and surgeries were conducted in accordance with standards and policies of the National Institutes of Health, and the institutional animal care and use committee at Mayo Clinic reviewed and approved all procedures. For all surgical procedures and experimental measurements, animals were anesthetized with an intramuscular injection of ketamine (90 mg/kg) and xylazine (10 mg/kg).
SH
As previously validated and reported (Gransee et al., 2013 (Gransee et al., , 2015 Mantilla et al., 2007 Mantilla et al., , 2012 Mantilla et al., , 2013a Mantilla et al., , 2013b Martinez-Galvez et al., 2016; Miyata et al., 1995; Prakash et al., 1999; Zhan et al., 1997) , rats underwent a dorsal C2 laminectomy and a right anterolateral cord transection in which the dorsal funiculi were preserved and the lateral and ventral funiculi were injured. This procedure was performed with a microknife. Acetaminophen (100-300 mg/kg) was given orally for the first 3 days, and intramuscular buprenorphine (0.1 mg/kg) was administered as required.
Chronic diaphragm electromyography recordings
Three days before SH surgery, two pairs of electrode wires (Cooner Wire, Chatsworth, CA) were implanted into the left and the right midcostal hemidiaphragm in a manner such that an uninsulated 3-mm segment was embedded within the diaphragm, as previously described (Dow et al., 2006 (Dow et al., , 2009 Gransee et al., 2013 Gransee et al., , 2015 Mantilla et al., 2011 Mantilla et al., , 2013a Mantilla et al., , 2013b Martinez-Galvez et al., 2016; Trelease et al., 1982) . The electrode wires were tunneled subcutaneously and externalized in the back of the animal.
To verify completeness of SH, absence of ipsilateral diaphragm electromyography (EMG) activity was confirmed under anesthesia at the time of surgery and 3 days post-SH (SH 3 days). Previous studies by our group have evaluated the extent of histological damage after unilateral SH (Mantilla et al., 2014; Miyata et al., 1995; Sieck and Mantilla, 2009) . The SH injury consistently results in damage to the ventral and lateral columns at C2, resulting in absence of ipsilateral diaphragm EMG activity at SH 3 days. Thus, a functional outcome was used to verify completeness of SH in the present study. Tissue procurement for laser capture microdissection (LCM) precludes additional histological analyses. Diaphragm EMG activity was also recorded for 5 minutes in anesthetized animals at SH 7, SH 14, and SH 28 days. EMG signals were amplified (32,000) and bandpass filtered between 20 Hz and 1 kHz (model 2124; DATA Inc.). Information was converted from analog to digital signals at 2 kHz with a LabView data acquisition board and software (National Instruments, Austin, TX). Root mean square (RMS) EMG amplitude was calculated with a 50-msec moving window (Mantilla et al., , 2011 (Mantilla et al., , 2013b Seven et al., 2013; Sieck and Fournier, 1990) . The entire recording was used for analysis, excluding only the occasional spontaneous deep breath (defined as an inspiratory burst greater than twice eupneic RMS EMG amplitude). An animal was classified as exhibiting recovery if the diaphragm EMG signal 1) was rhythmic (i.e., in phase with the contralateral side) and periodic (i.e., occurring on at least 90% of eupneic bursts); 2) reflected activation of more than one motor unit (identified by EMG spikes with more than one morphology consistent with more than one motor unit); and 3) had RMS EMG amplitude at least 10% of the pre-SH amplitude. Respiratory rate and duty cycle (percentage of time with inspiratory activity) were calculated from contralateral diaphragm EMG recordings. Just as in previous studies, DIAm EMG recordings during eupnea reflected <5% variance in respiratory rate or RMS EMG amplitude.
Phrenic motoneuron transduction with AAV vectors
For analyses of phrenic motoneuron receptor expression, rats were assigned to one of five groups (see Table 2 ): untreated control (n 5 7), AAV-TrkB-treated control (n 5 5), untreated SH (n 5 5), AAV-GFP-treated SH (n 5 10), and AAV-TrkB-treated SH (n 5 9). AAV7 encoding GFP (AAV7.CMV.eGFP.WPRE.bGH) and AAV7 encoding human TrkB (AAV7.CMV.Flag-TrkB.WPRE. bGH) were obtained from the Vector Core at the University of Pennsylvania (Philadelphia, PA). It is worth noting that the AAV-TrkB vector encodes both the fulllength human TrkB receptor and the FLAG protein; however, it is not a FLAG-tagged TrkB receptor fusion protein. The AAV7 serotype was selected based on its selective retrograde transduction of phrenic motoneurons (Gransee et al., 2013) . Specifically, AAV-based delivery of human TrkB to phrenic motoneurons was verified by evidence of human TrkB mRNA expression in microdissected phrenic motoneurons as well as measurements of FLAG protein expression in cervical spinal cord homogenates at 3 weeks after intrapleural injection. Three weeks prior to SH surgery, AAV-GFP or AAV-TrkB was administered via unilateral intrapleural injection (50 ll; 1 3 10 11 genome copies/side) as previously described (Gransee et al., 2013; Mantilla et al., 2009) . Briefly this technique consists of an injection of AAV in the pleural space between the seventh and eighth ribs of the right chest. Animals were killed 5 weeks after AAV injection. Injection with AAV did not result in any adverse effects; all animals displayed normal weight gain and behavior compared with the untreated groups.
Retrograde labeling of phrenic motoneurons
Intrapleural injection of cholera toxin subunit B (CTB) was used to label phrenic motoneurons retrogradely (Gransee et al., 2013 (Gransee et al., , 2015 Issa et al., 2010; Mantilla et al., 2009 Mantilla et al., , 2012 Martinez-Galvez et al., 2016) . We previously confirmed that intrapleural injection of CTB labels only phrenic motoneurons in the cervical spinal cord . Briefly, 3 days before the terminal experiment, 20 ll of a 0.2% solution of Alexa Fluor 488-conjugated CTB or Alexa Fluor 555-conjugated CTB (Molecular Probes/Life Technologies, Grand Island, NY) was injected with a Hamilton syringe into the pleural space of the right side and the left side of the chest between the seventh and eighth ribs.
LCM of phrenic motoneurons
LCM was used to obtain a pure population of phrenic motoneurons from spinal cord sections as previously described (Gransee et al., 2013; Mantilla et al., 2012; Martinez-Galvez et al., 2016) . After the animals were anesthetized and then killed by exsanguination, the cervical spinal cord (C2-C7) was removed and quickly frozen in liquid N 2 under RNase-free conditions. Longitudinal sections of spinal cord were cut (10 lm), placed on prechilled slides (Fisher Scientific, Pittsburgh, PA), and stored at 280 8C until microdissection. Slides were dehydrated in graded alcohols and xylene immediately before LCM. With the Arcturus XT LCM microdissection system (Applied Biosystems/Life Technologies, Carlsbad, CA), it was possible to visualize retrogradely labeled phrenic motoneurons under direct epifluorescence illumination (see Fig. 2 ) and to microdissect selected motoneurons onto Capsure HS LCM caps (Life Technologies). In most cases, a single cap was used for three or four spinal cord sections, and an average of four caps was obtained from the right side of the spinal cord (ipsilateral to SH) for each animal. Caps were stored at 280 8C until RNA extraction.
Real-time RT-PCR
Total RNA was extracted from the LCM samples with the RNeasy Micro kit (Qiagen, Valencia, CA) according to the manufacturer's protocol and then pooled for all caps from the same animal. The RNA was reverse transcribed with the Transcriptor First Strand cDNA Synthesis kit (Roche Applied Science, Indianapolis, IN) under standard conditions as previously described (Mantilla et al., 2012; Martinez-Galvez et al., 2016) . Briefly, sample RNA (in duplicate for each sample), random hexamer primer, anchored-oligo(dT)18 primer, and RNasefree sterile water were incubated at 65 8C for 10 minutes and chilled on ice for 1 minute. A mixture of 1 3 Transcriptor reverse transcriptase reaction buffer, Protector RNase inhibitor, dNTP, and Transcriptor reverse transcriptase was added to each sample. Samples were incubated for 10 minutes at room temperature, followed by 20 minutes at 55 8C. Finally, samples were heated to 85 8C for 5 minutes and placed on ice.
For gene expression analysis, quantitative amplification of specific receptor subtypes was studied with 1 3 Sybr Green I Master on a LightCycler 480 (Roche Applied Science) and the primer pair (5 0 and 3 0 primers)
for each receptor as previously described (Mantilla et al., 2012) . These receptors include NMDA NR1 subunit, AMPA GluR2 subunit, mGluR1, and mGluR5. The ribosomal protein S16 (RPS16) was used as a reference gene. Uniform expression of RPS16 among experimental groups was verified. Amplification and quantitation of mRNA were performed on a LightCycler 480. The thermal cycling conditions were identical: 5-minute preamplification incubation at 95 8C, 70 cycles of primer annealing at 60 8C for 12 seconds, PCR product extension at 72 8C for 18 seconds, and denaturing at 95 8C for 15 seconds. To verify specificity of the amplification product, a melting curve analysis was performed, plotting the derivative of the melting curve fluorescence (2dF/dT) vs. temperature. An appropriate single peak in the resultant melting curve and the lack of primerdimer complexes were indicators of correct amplification products. DNA electrophoresis was previously performed to verify the specificity of the PCR product (Mantilla et al., 2012) . All PCRs were performed in duplicate for each reverse transcription product.
Quantitative analyses
LightCycler 480 software (version 1.5; Roche Applied Science) was used to generate a fluorescence plot for each sample (see Fig. 2G ). To determine the threshold cycle (i.e., crossing point [CP]), the point at which each gene product transitions from the linear phase to the logarithmic phase, the second derivative method was applied to the amplification curve. The difference in CP from the reference gene RPS16 was then calculated to determine a DCP for each sample and transcript. The DCP reveals relative changes in receptor mRNA expression for each glutamatergic receptor subtype after SH. RT and PCRs were conducted in duplicate (i.e., at least four measurements per transcript for each animal). Prior to statistical analysis for each glutamatergic receptor subtype, outliers were removed when DCP was greater than three cycles away from the median DCP for each animal.
Statistical analysis
All statistical evaluations were performed in JMP statistical software (JMP 10.0; SAS Institute, Cary, NC). The proportion of animals displaying recovery of ipsilateral diaphragm muscle activity was compared across treatment groups with a repeated-measures nominal logistic test (time 3 treatment). Diaphragm RMS EMG amplitude was normalized to the eupneic value before SH for the same animal, and differences between groups were examined with one-way ANOVA. Respiratory rate and duty cycles were compared with mixed linear models with repeated measures (time 3 AAV treatment) and animal as a random effect. Glutamatergic receptor subtype expression was also compared by one-way ANOVA. When applicable, post hoc analyses were conducted with Tukey-Kramer's honestly significant difference (HSD) test. The correlation between transcripts was calculated by linear regression after calculating a Z-score for each transcript and sample in the entire population. The degree of correlation is expressed as the r 2 value, with the effectiveness of the model (difference from the mean response) determined by ANOVA. Statistical significance was established at 0.05. All experimental data are mean 6 SE unless otherwise specified.
RESULTS
In total, 36 animals were used across studies. All SH animals (n 5 24) were implanted with bilateral diaphragm EMG electrodes 3 days before SH surgery. Just as in previous studies, diaphragm EMG was recorded during SH surgery and at SH 3 days to confirm completeness of SH by absence of ipsilateral diaphragm EMG activity during eupnea in anesthetized animals (Gransee et al., 2013 (Gransee et al., , 2015 Mantilla et al., 2013a,b; Martinez-Galvez et al., 2016; Miyata et al., 1995; Prakash et al., 1999; Zhan et al., 1997) . One SH animal displayed ipsilateral diaphragm eupneic EMG activity at SH 3 days and was excluded.
Recovery of ipsilateral diaphragm muscle activity post-SH Diaphragm EMG activity during eupnea was recorded until SH 14 days. Both ipsilateral and contralateral diaphragm EMG activity occurred in bursts, reflecting rhythmic inspiration in anesthetized animals (Fig. 1) . During a recording session, minimal variability in diaphragm RMS EMG amplitude was evident (variance < 5%). Over time post-SH, a subset of animals displayed spontaneous recovery of ipsilateral diaphragm EMG activity during eupnea. At SH 7 and at SH 14 days, three from among five untreated SH animals (60%) displayed recovery (Fig. 1B) . In general agreement with previous studies (Gransee et al., 2013; Martinez-Galvez et al., 2016) , the proportion of animals displaying recovery of ipsilateral diaphragm muscle n 5 48] 5 12.61, P 5 0.027) and was significantly higher in the AAV-TrkB-treated SH group. There were no time (P 5 0.115) or time 3 treatment interaction (P 5 0.147) effects on recovery. In animals treated with AAV-TrkB, six of nine animals (67%) displayed recovery at SH 7 days, and all animals had recovered by SH 14 days. In animals treated with AAV-GFP, four of 10 animals (40%) displayed recovery of ipsilateral EMG activity at SH 7 and at SH 14 days.
Extent of eupneic diaphragm EMG activity post-SH
Diaphragm RMS EMG amplitude was assessed to determine the extent of recovery of eupneic diaphragm EMG activity post-SH. Diaphragm RMS EMG amplitude at SH 7 and at SH 14 days was normalized to the amplitude before SH for the same animal. There was a statistically significant difference across treatment groups in the extent of recovery post-SH (F 2,23 5 7.29; P 5 0.004). At SH 14 days, RMS EMG amplitude was 32% 6 17% of the pre-SH value in the untreated SH animals (Fig. 1C) , including both those that displayed recovery and those that did not. If only untreated SH animals that displayed recovery are considered, RMS EMG amplitude was 53% 6 20% of the pre-SH value. Treatment with AAV-TrkB significantly increased the extent of recovery at SH 14 days; diaphragm RMS EMG amplitude was 95% 6 24% of the pre-SH value in AAVTrkB-treated SH animals and was significantly different from that of AAV-GFP-treated SH animals (P < 0.05). Treatment with AAV-GFP did not change the extent of recovery compared with untreated SH. At SH 14 days, RMS EMG amplitude was 12% 6 6% of the pre-SH value in AAV-GFP-treated SH animals, including both those Figure 1 . Ipsilateral diaphragm EMG activity during eupnea post-SH. A: Representative raw diaphragm EMG recordings and RMS EMG tracings post-SH. Untreated SH animals (SH; n 5 5), AAV-GFP-treated SH animals (SH 1 AAV-GFP; n 5 10), and AAV-TrkB-treated SH animals (SH 1 AAV-TrkB; n 5 9) were chronically monitored with EMG recordings obtained via implanted diaphragm electrodes. EMG was recorded pre-SH and at SH 3 and SH 14 days. B: Proportion of animals displaying recovery of ipsilateral diaphragm EMG activity during eupnea post-SH. The criteria for recovery are detailed in Methods and Materials. Diaphragm EMG activity was absent at SH 3 days in all animals, confirming complete interruption of descending ipsilateral drive to phrenic motoneurons and diaphragm muscle paralysis. At SH 7 days, the proportion of animals recovered was the same across groups (P 5 0.490). By SH 14 days, all of the AAV-TrkB-treated SH animals showed recovery compared with four from among 10 AAV-GFP-treated SH animals and three of five untreated SH animals. *P 5 0.027. C: Extent of recovery of ipsilateral diaphragm EMG activity at SH 14 days. In untreated SH and AAV-GFP-treated SH animals, RMS EMG amplitude was reduced at SH 14 days compared with pre-SH. Treatment with AAV-TrkB increased the extent of diaphragm activity post-SH compared with AAV-GFP-treated SH. *P 5 0.004.
that displayed recovery and those that did not. In AAV-GFP-treated SH animals that displayed recovery, RMS EMG amplitude was 31% 6 9% of the pre-SH value.
There were no differences in contralateral diaphragm RMS EMG amplitude across groups at SH 14 days (F 2,22 5 0.06; P 5 0.945). Contralateral RMS EMG amplitude was 165% 6 37% of the pre-SH value in animals that did not display recovery at SH 14 days (n 5 8) and 159% 6 23% of the pre-SH value in animals that displayed recovery (n 5 15). These results are consistent with previous studies with SH animals (Gransee et al., 2013 (Gransee et al., , 2015 Mantilla et al., 2013a,b; Martinez-Galvez et al., 2016) .
Respiratory rate and duty cycle were measured from the contralateral hemidiaphragm EMG recordings during eupnea pre-SH and at SH 14 days (Table 1) . Respiratory rate was unaffected by SH and/or AAV treatment (mixed linear model; group P 5 0.075, treatment P 5 0.244, interaction P 5 0.275). Similarly, duty cycle was unaffected by SH and/or AAV treatment (mixed linear model; group P 5 0.366, treatment P 5 0.060, interaction P 5 0.336).
LCM of phrenic motoneurons
Retrogradely labeled phrenic motoneurons were visualized via Alexa 488 or Alexa 555 fluorescence after intrapleural injection of fluorescently conjugated CTB. Phrenic motoneurons were localized in a rostrocaudal column within the gray matter of cervical spinal cord segments C3-C5 as described previously (Kinkead et al., 1998; Mantilla et al., 2009 Mantilla et al., , 2012 MartinezGalvez et al., 2016; Prakash et al., 1993 Prakash et al., , 2000 Zhan et al., 1989) . Visual inspection of the LCM cap and the remaining spinal cord tissue confirmed complete capture of phrenic motoneurons (Fig. 2) . Most phrenic motoneurons on the side of the SH injury were captured (80%). On average, 176 6 13 phrenic motoneurons were captured per animal. A subset of AAV-GFPtreated SH animals (n 5 5) was retrogradely labeled with Alexa 555-conjugated CTB to estimate the AAV transduction efficiency. Phrenic motoneurons expressing both GFP and Alexa 555 fluorescence were successfully microdissected separately from phrenic motoneurons expressing only Alexa 555 fluorescence, and AAV transduction efficiency was estimated as the ratio of GFP-positive captures compared with the total number of phrenic motoneurons (CTB-positive). GFP expression was evident only in motoneurons colabeled with CTB, indicating that intrapleural AAV-GFP transduced only phrenic motoneurons. Transduction efficiency was 16% 6 2%, consistent with a previous report (Gransee et al., 2013) .
Glutamatergic receptor expression in phrenic motoneurons
Just as in previous studies (Mantilla et al., 2012; Martinez-Galvez et al., 2016) , expression of glutamatergic receptors (NMDA NR1 subunit, AMPA GluR2 subunit, mGluR1, and mGluR5) and RPS16 in microdissected phrenic motoneurons was quantified with real-time RT-PCR. A melting curve analysis for all transcripts was performed to verify the specificity of amplification of the corresponding primer pair for each PCR, and a single peak at an appropriate temperature was identified for each. Representative amplification curves for all transcripts are shown in Figure 2 .
The number of animals with detectable mRNA expression levels in each experimental group stratified by recovery post-SH is shown in Table 2 . NMDA NR1 subunit was consistently found across groups (in 34 from among 36 animals examined), independent of recovery status. AMPA GluR2 subunit was consistently found in all groups except the AAV-GFP-treated SH group, and its expression was significantly more consistent in recovered compared with nonrecovered animals (v 2 [1, n 5 36] 5 4.082, P 5 0.043). mGluR1 was found in all control animals but was found less consistently in other groups and was not detectable in any of the AAV-GFP-treated SH animals. Expression of mGluR5 also was not consistently found across groups and was undetectable in AAV-TrkB-treated animals. Ventilatory parameter SH (n 5 5) SH 1 AAV-GFP (n 5 10) SH 1 AAV-TrkB (n 5 9)
Pre-SH Respiratory rate (minute 21 ) 7 3 6 4 7 8 6 4 7 8 6 5 Duty cycle (%) 30 6 3 4 0 6 4 3 3 6 3 SH 14 days
Respiratory rate (minute 21 ) 8 0 6 4 7 8 6 4 9 0 6 4 Duty cycle (%) 37 6 3 4 0 6 2 3 2 6 2 1 Data are mean 6 SE. Duty cycle was calculated as the percentage of total time corresponding to inspiration. There were no differences in respiratory rate or duty cycle between experimental groups or time.
Glutamatergic expression following recovery
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Phrenic motoneuron expression of glutamatergic receptors across groups is shown in Table 3 . Phrenic motoneuron expression of NMDA NR1 subunit was significantly increased in all three SH groups (overall F 4,33 5 15.06; P < 0.001). Post hoc comparisons with Tukey-Kramer HSD revealed that NR1 subunit In a subset of AAV-GFP-treated SH animals, phrenic motoneurons were retrogradely labeled with Alexa 555-conjugated CTB. E: Phrenic motoneurons from D that also expressed GFP (indicated by arrows) were used to estimate transduction efficiency of AAV-GFP. F: Low-magnification image of LCM cap shows column of phrenic motoneurons captured from spinal cord sections. G: Representative amplification curves for each transcript across all experimental groups. Groups include control (CTL), AAVTrkB-treated control (AAV-TrkB), untreated SH (SH), AAV-GFP-treated SH (SH 1 AAV-GFP), and AAV-TrkBtreated SH (SH 1 AAV-TrkB). Quantification of receptor expression was performed with the second derivative method for CP analyses. Expression level (DCP) for each sample and transcript was found by the difference between CPs for receptor transcript and RPS16. Scale bars 5 100 lm in A (applies to A-E); 500 lm in F.
expression was greater in AAV-TrkB-treated SH animals compared with AAV-GFP-treated SH animals (P 5 0.004). The change in DCP for phrenic motoneurons in AAV-TrkB-treated SH animals represents an approximately fourfold increase in NMDA NR1 subunit expression relative to AAV-GFP-treated SH animals. Phrenic motoneuron expression of AMPA GluR2 subunit significantly decreased (corresponding to an increased DCP) in AAV-TrkB-treated controls and in all SH groups (overall F 4,27 5 17.82; P < 0.001). Expression of mGluR1 remained unchanged across SH groups (overall F 3,15 5 4.09; P 5 0.033), and, although it was significantly greater in AAV-TrkB-treated control animals compared with untreated SH, mGluR1 expression was not consistent across groups, as noted above, resulting in low animal numbers (Table 2) . Phrenic motoneuron expression of mGluR5 did not change across groups (F 3,14 5 1.98; P 5 0.175).
In addition, the role of AAV treatment was assessed by examining expression of glutamatergic receptors in phrenic motoneurons expressing GFP (indicating AAV transduction) separately from those not expressing GFP in a subset of AAV-GFP-treated SH animals (n 5 5). AAV-GFP transduction had no effect on phrenic motoneuron expression of NMDA NR1 subunit (F 1,9 5 2.04; P 5 0.191), AMPA GluR2 subunit (F 1,9 5 0.21; P 5 0.657), or mGluR5 (F 1,5 5 1.18; P 5 0.338). Taken together, these results support a minimal nonspecific effect of AAV transduction on phrenic motoneuron expression of glutamatergic receptors.
To evaluate correlations within animals in the expression of glutamatergic receptors, Z-scores for each transcript and sample were determined with the entire animal population (all five experimental groups). Correlations were analyzed with pairwise comparisons, and the only receptor pair that displayed a significant correlation across groups was AMPA GluR2 subunit-NMDA NR1 subunit (Fig. 3) . In Figure 3 , control animals are shown clustered in the upper left quadrant, reflecting relatively lower NMDA NR1 subunit expression with higher AMPA GluR2 subunit expression in this group. In addition, there was a significant, positive correlation between AMPA GluR2 and NMDA NR1 subunit expression in SH animals (F 1,17 5 11.51; P 5 0.004; slope 5 0.55; r 2 5 0.42). AAV-TrkB-treated SH animals are shown clustered in the right quadrants, reflecting higher relative expression of NR1 subunit. Animals were divided into recovered (Rec) and nonrecovered (Non) groups based on evidence of rhythmic ipsilateral diaphragm muscle activity.
For each transcript, the number of animals in which the transcript was detected by RT-PCR is indicated and may differ from the total number of animals in the group. In particular, mGluR1 and mGluR5 receptor mRNA expression was not consistently detectable in all animals.
2 Number of animals in each group.
3
Number of animals that recovered in SH groups (-, not applicable). NMDA NR1 subunit 11.6 6 0.6 9.6 6 0. Significantly different from SH 1 AAV-GFP.
Glutamatergic expression following recovery
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The extent of ipsilateral diaphragm activity at SH 14 days (expressed as percentage of pre-SH amplitude) was compared with glutamatergic receptor expression for each SH animal (Fig. 4) . There was a significant correlation between diaphragm activity post-SH and NMDA NR1 subunit DCP (F 1,22 5 6.19; P 5 0.021; slope 5 18.6; r 2 5 0.23), indicating that animals with greater extent of recovery of diaphragm activity had higher NMDA NR1 subunit expression (corresponding to a higher DCP). There was no significant correlation between diaphragm activity and AMPA GluR2 subunit DCP (F 1,17 5 0.57; P 5 0.461; slope 5 8.9; r 2 5 0.03).
In an additional analysis of glutamatergic receptor expression, animals across all SH experimental groups were grouped by recovery of rhythmic diaphragm EMG activity at SH 14 days and compared with control animals. Phrenic motoneuron mRNA expression of NMDA NR1 subunit (F 2,28 5 24.91; P < 0.001) and AMPA GluR2 subunit (F 2,22 5 32.48; P < 0.001) was affected by SH and by evidence of recovery after SH (Fig. 4) . Phrenic motoneuron NR1 subunit mRNA expression was significantly greater in both nonrecovered and recovered SH animals compared with control. In addition, NR1 subunit expression was greater in SH animals displaying recovery compared with nonrecovered animals. Phrenic motoneuron GluR2 subunit mRNA expression was significantly less in both nonrecovered and recovered SH animals compared with control. SH animals displaying recovery had significantly greater GluR2 subunit expression compared with nonrecovered animals.
DISCUSSION
The results of this study support the importance of glutamatergic receptor expression in recovery of ipsilateral rhythmic diaphragm muscle activity after SH in models of spontaneous and TrkB-mediated enhanced recovery. In animals displaying recovery of diaphragm activity, NMDA NR1 subunit mRNA expression in phrenic motoneurons increased approximately fourfold compared with animals in which recovery was not present. Ipsilateral diaphragm activity post-SH was also significantly correlated to NMDA NR1 expression in phrenic motoneurons. In contrast, phrenic motoneuron AMPA GluR2 subunit mRNA expression decreased after SH, and, albeit increased in animals displaying recovery vs. those not recovering, levels remained lower than control, and no correlation with diaphragm activity was evident. We conclude that recovery of diaphragm muscle activity after incomplete cervical SCI is associated with increased phrenic motoneuron expression of glutamatergic NMDA receptors.
Glutamatergic receptor subunit mRNA expression in phrenic motoneurons post-SH Excitatory bulbospinal (premotor) respiratory drive to phrenic motoneurons is primarily glutamatergic (Greer et al., 1992; McCrimmon et al., 1989; Saji and Miura, 1990) . Phrenic motoneurons express multiple excitatory glutamatergic receptor subtypes, including ionotropic NMDA and AMPA receptors as well as metabotropic mGluR1 and mGluR5 (Chitravanshi and Sapru, 1996; Dong and Feldman, 1999; Robinson and Ellenberger, 1997) . Expression of mRNA for all of these receptors was confirmed in laser capture-microdissected phrenic motoneurons (present study; Mantilla et al., 2012) . Both NMDA and AMPA receptors located in the phrenic motor nucleus play an important role in neurotransmission of inspiratory drive (Chitravanshi and Sapru, 1996; Pierrefiche et al., 1994; Robinson and Ellenberger, 1997) .
In the present study, phrenic motoneuron expression of NMDA NR1 subunit mRNA increased in those animals displaying recovery of diaphragm muscle activity, both spontaneous and enhanced by AAV-mediated increase in TrkB expression, compared with animals Figure 3 . Correlation between phrenic motoneuron expression of NMDA NR1 subunit and AMPA GluR2 subunit after SH. Each point represents the Z-score for transcript expression for an individual animal, which was calculated from the mean DCP across PCRs for that animal and overall mean and SD for all animals from all groups. Solid symbols indicate animals that showed recovery at any point beyond 3 days post-SH. Correlated changes in expression (increase or decrease) across experimental groups are evident by clustering within a quadrant (right upper quadrant represents increased expression for both transcripts and left lower quadrant represents decreased expression). Only the SH, SH 1 AAV-GFP, and SH 1 AAV-TrkB groups are shown for the sake of clarity (see text).
that did not display recovery at SH 14 days as well as uninjured controls. In addition, there was a significant relationship between diaphragm muscle activity and NMDA NR1 subunit expression such that animals with higher extent of recovery post-SH had higher NMDA NR1 subunit expression. The NR1 subunit was chosen in the present study because it is mandatory for all NMDA receptors (Paoletti et al., 2013; Traynelis et al., 2010) . A contribution of NMDA receptor signaling in phrenic motoneurons to recovery post-SH was also suggested by changes in NMDA receptor mRNA and protein expression in cervical spinal cord homogenates (Alilain and Goshgarian, 2008) , by quantitative NMDA receptor mRNA measurements in retrogradely labeled motoneurons (Mantilla et al., 2012) , and by NMDA receptor immunohistochemical staining in putative phrenic motoneurons (Alilain and Goshgarian, 2008) .
As with the NMDA NR1 subunit, phrenic motoneuron expression of AMPA GluR2 subunit mRNA increased in animals displaying recovery compared with animals that did not display recovery at SH 14 days. Unlike the NMDA NR1 subunit, there was no relationship between diaphragm muscle activity and AMPA GluR2 subunit expression post-SH. GluR2 subunit mRNA expression remained less in all SH groups compared with uninjured control. This is consistent with previous studies in Figure 4 . Relationship between phrenic motoneuron expression of glutamatergic receptors and diaphragm activity after SH. A: There was a significant correlation between diaphragm activity post-SH and NMDA NR1 subunit DCP (P 5 0.021), indicating that animals with greater extent of recovery of diaphragm activity had higher NMDA NR1 subunit mRNA expression (corresponding to a higher DCP). There was no significant correlation between diaphragm activity and AMPA GluR2 subunit mRNA expression (P 5 0.461). Solid symbols indicate animals that displayed recovery at any point beyond 3 days post-SH. B: Phrenic motoneuron NMDA NR1 subunit mRNA expression was significantly greater in SH animals compared with control (*P < 0.001), and NMDA NR1 subunit expression was greater in SH animals displaying recovery (Rec) than in nonrecovered animals (Non-Rec; †P < 0.001). Phrenic motoneuron AMPA GluR2 subunit mRNA expression was significantly less in SH animals compared with control. SH animals displaying recovery had significantly greater AMPA GluR2 subunit expression compared with nonrecovered animals.
which AMPA GluR2 receptor expression decreased in spinal cord at levels below the injury (but not just motoneurons) after SH (Alilain and Goshgarian, 2008) . At present, the ability to measure motoneuron excitability in a motoneuron pool in vivo remains limited. Nonetheless, it is likely that an increase in NMDA receptor expression at motoneurons, even with a decrease in AMPA receptor, will increase excitability because of longer duration excitatory postsynaptic currents and slower receptor desensitization kinetics (Rekling et al., 2000) .
Differences in the relative distribution of glutamatergic receptors may also contribute to recovery after SCI. For instance, retrogradely labeled phrenic motoneurons displayed immunoreactivity for the NMDA NR1 subunit at the somata but not at the dendrites (Robinson and Ellenberger, 1997) . In contrast, almost all retrogradely labeled phrenic motoneurons were immunoreactive for AMPA GluR2 in both the somata and the dendrites (Robinson and Ellenberger, 1997) . Accordingly, a change of glutamatergic signaling to the motoneuron somata would be expected to contribute to increased motoneuron discharge rates in response to similar synaptic inputs.
Future studies could elucidate changes in phrenic motoneuron expression of other glutamatergic receptor subunits. For instance, expression of postsynaptic NMDA receptors with varying subunit composition also regulates motoneuron excitability (Traynelis et al., 2010) . In particular, NMDA NR2 subunits display varying sensitivity to Mg 21 blockade as well as deactivation kinetics (Glasgow et al., 2015; Siegler Retchless et al., 2012) . Similarly, AMPA receptor function may differ in receptors lacking the GluR2 subunit. Thus, a systematic assessment of motoneuron glutamatergic receptor expression including various subunit types and their relative distribution along the motoneuron dendritic tree would further the understanding of the role of glutamatergic signaling to enhanced functional recovery after SCI.
BDNF/TrkB signaling in recovery after SCI
Previous studies have indicated that BDNF/TrkB signaling enhances spontaneous recovery post-SH (Gransee et al., 2013 (Gransee et al., , 2015 Mantilla et al., 2013a; MartinezGalvez et al., 2016) and regulates NMDA receptor expression in other neuronal systems. BDNF signaling through TrkB plays an important role in recovery after SCI (Bregman et al., 2002; Coumans et al., 2001; Friedman et al., 1995; Gill et al., 2016) . Recovery of ipsilateral diaphragm muscle activity after SH was enhanced by delivery of exogenous BDNF via either intrathecal infusion (Mantilla et al., 2013a) or intraspinal transplantation of mesenchymal stem cells engineered to release BDNF (Gransee et al., 2015) . Conversely, recovery post-SH was prevented by delivery of a TrkBFc fusion protein to the region of the phrenic motoneuron pool that binds endogenous BDNF. Furthermore, recovery post-SH was blunted by siRNA-mediated downregulation of TrkB receptor expression in phrenic motoneurons (Mantilla et al., 2013a) or selective inhibition of TrkB kinase activity with a chemical-genetic approach in TrkB F616A mice (Mantilla et al., 2014) . Finally, selective retrograde transduction of phrenic motoneurons with intrapleural AAV7 encoding TrkB enhanced recovery of ipsilateral diaphragm muscle activity post-SH (Gransee et al., 2013; Martinez-Galvez et al., 2016) . With the goal of evaluating shared changes in glutamatergic receptor expression between animals with spontaneous and TrkB-mediated enhanced recovery, the present study used the regimen of pretreatment with AAV-TrkB to provide the most robust recovery of diaphragm activity after SH. Our previous study confirmed AAV delivery to phrenic motoneurons with an AAV encoding for both the full-length human TrkB receptor and the FLAG protein by evidence of human TrkB mRNA expression in microdissected phrenic motoneurons and measurements of FLAG protein expression in cervical spinal cord homogenates (Gransee et al., 2013) . Tissue procurement for LCM precluded such analyses in the present study; however, the functional effects of AAV-TrkB treatment in the present study replicated those in our previous validation study in which AAV-TrkB administered 3 weeks before SH also resulted in recovery of diaphragm activity in 100% of animals at SH 14 days (Gransee et al., 2013 ). In contrast, 67% of animals displayed recovery after AAVTrkB was administered 3 days after SH (Martinez-Galvez et al., 2016) , consistent with a more delayed increase in motoneuron TrkB expression with the later administration. Providing additional support that the enhancement of spontaneous recovery mediated by AAV-TrkB treatment is the result of increased TrkB expression in phrenic motoneurons rather than nonspecific effects of AAV treatment, intrapleural injection of AAV-GFP did not enhance recovery, resulting in the present study's optimized assessment of the role of increased BDNF/ TrkB signaling at phrenic motoneurons in regulating motoneuron glutamatergic receptor expression.
Regulation of glutamatergic receptor expression by BDNF/TrkB signaling
There is evidence that BDNF/TrkB signaling regulates both pre-and postsynaptic plasticity in various neuronal systems, including the spinal cord, and acts as a bidirectional modulator of excitatory synaptic transmission (Carvalho et al., 2008) . Presynaptically, BDNF allows persistent glutamate release during action potentials, thereby enhancing synaptic responses and allowing an increase in docking of synaptic vesicles to the plasma membrane in hippocampal slices (Jovanovic et al., 2000; Tyler and Pozzo-Miller, 2001 ). Postsynaptically, BDNF/TrkB signaling regulates phosphorylation of NMDA or AMPA receptor subunits contributing to longterm potentiation of synaptic transmission in synaptosomes (Lin et al., 1998; Suen et al., 1997) and hippocampal neurons (Caldeira et al., 2007; Kang and Schuman, 1995; Lessmann et al., 1994) . In general agreement with the studies cited above, the present study demonstrates that, when recovery of diaphragm muscle activity is enhanced by AAV-mediated upregulation of TrkB receptor expression in phrenic motoneurons, expression of both NMDA NR1 subunit and AMPA GluR2 subunit mRNA also increases, suggesting an association with increased BDNF/TrkB signaling. Based on these studies, it appears that postsynaptic mechanisms evoked by BDNF/TrkB signaling are sufficient to enhance recovery and may be mediated by regulating excitatory NMDA and AMPA receptor glutamatergic neurotransmission in phrenic motoneurons post-SH.
The specific mechanism underlying how increased TrkB receptor expression regulates glutamatergic receptor expression (NMDA receptor and AMPA receptor) in motoneurons is not presently known and requires additional investigation. Although BDNF/TrkB signaling may exert acute effects on glutamatergic neurotransmission (e.g., via NMDA receptor phosphorylation; Crozier et al., 2008; Slack and Thompson, 2002) , changes in NMDA receptor mRNA expression (as in the present study) likely reflect long-term changes in synaptic efficacy. Whether postsynaptic changes in Ca 21 signaling via NMDA receptors (as in hippocampus [Lin et al., 1998] or postnatal spinal cord [Arvanian and Mendell, 2001] ) are required for the expression of synaptic plasticity and enhanced neurotransmission at phrenic motoneurons is unclear. Furthermore, it is not clear that NMDA receptor upregulation post-SH follows the same mechanism as that induced by AAV-TrkB treatment. Increased NMDA NR1 subunit mRNA expression in AAV-TrkBtreated SH animals is the result of increased TrkB rather than effects of AAV, given that expression of NR1 was the same in phrenic motoneurons transduced with AAV-GFP compared with those that were not transduced. Regardless, the present study supports manipulating neurotrophic signaling in motoneurons as sufficient to produce sustained enhancement of recovery after incomplete SCI.
Expression of glutamatergic receptor mRNA was assessed with real-time RT-PCR measurements in identified phrenic motoneurons sampled with LCM. This strategy has been used previously to document the time course of changes after SH (Mantilla et al., 2012) . After intrapleural AAV-GFP treatment, there is evidence of GFP in 16% of retrogradely labeled motoneurons (present study; Gransee et al., 2013) . To ensure inclusion of a sufficiently large number of transduced motoneurons, we sampled as many motoneurons as possible from the ipsilateral spinal cord. On average, 176 6 13 motoneurons were captured per animal in the present study, representing a large proportion of the total number of phrenic motoneurons present on one side of the cervical spinal cord (224 6 21 phrenic motoneurons/ side in Sprague-Dawley rats; Mantilla et al., 2009) . It is noteworthy that changes in NMDA and AMPA receptor expression were present in microdissected phrenic motoneurons after AAV-TrkB treatment. Because of the large size of the TrkB gene, packaging of a large reporter gene (e.g., GFP) was not technically possible, so it was not feasible to distinguish which phrenic motoneurons were transduced by AAV-TrkB and selectively sample those motoneurons with LCM. Regardless, even if few motoneurons overexpress human TrkB, they contribute to a robust change in glutamate receptor mRNA expression in the entire pool of motoneurons. These measurements highlight the strength of the approach using LCM compared with other methods that evaluate receptor expression (e.g., Western blot or immunofluorescence). Quantitative analyses of mRNA expression in microdissected motoneurons may indeed provide a much more sensitive assessment of viral transduction.
CONCLUSIONS
The results of this study show that NMDA receptormediated glutamatergic neurotransmission plays an important role in spontaneous recovery after SCI as well as the enhancement of recovery mediated by BDNF/TrkB signaling in phrenic motoneurons. Our results link the recovery of ipsilateral diaphragm muscle activity post-SH to an increase in phrenic motoneuron NMDA NR1 subunit expression that can be enhanced by increasing TrkB signaling in phrenic motoneurons and posit a new role for NMDA receptor neurotransmission in mediating BDNF/TrkB signaling effects on recovery. Understanding the concurrent effects of increased BDNF/TrkB signaling and altered phrenic motoneuron neurotransmitter receptor expression after SCI provides important insight for the identification and development of appropriate pharmacological targets to enhance recovery of diaphragm muscle activity after injury.
